Measurement of Patient Reported Gastrointestinal (GI) and Health-Related Quality of Life (HRQL) Outcomes in Simultaneous Pancreas-Kidney Transplant Recipients.
Phase of Trial: Phase III
Latest Information Update: 23 Dec 2010
At a glance
- Drugs Mycophenolate sodium (Primary)
- Indications Pancreas transplant rejection; Renal transplant rejection
- Focus Adverse reactions
- Sponsors Novartis
- 23 Dec 2010 Actual initiation date changed from Dec 2008 to Jan 2008 as reported by ClinicalTrials.gov.
- 23 Dec 2010 Last checked against ClinicalTrials.gov record.
- 18 Dec 2008 Planned number of patients changed from 130 to 32 as reported by ClinicalTrials.gov.